Akademik Veri Yönetim Sistemi
journal of enterocolitis, cilt.1, sa.3, ss.56-60, 2022 (Hakemli Dergi)
Objective: Irritable bowel syndrome is a common functional gastrointestinal disorder that affects the quality of life and the ability to work. It is known that
irritable bowel syndrome occurs as a result of a multifactorial change in microbiota and immunology. We aimed to evaluate the effects of Bacillus subtilis on
inflammatory parameters and quality of life in irritable bowel syndrome.
Methods: Irritable bowel syndrome volunteers diagnosed according to Rome IV criteria were recruited in the single-center prospective study and were given
5 billion B. subtilis once a day for 3 weeks. The primary outcome, the irritable bowel syndrome symptom severity score, fecal microbiota analysis, and serum
inflammatory parameters were evaluated at the beginning of the study and at the end of the 3-week study period.
Results: The mean age of 22 patients included in the study was 39.90 ± 11.93 years. The mean irritable bowel syndrome symptom severity score was 144.31
± 104.86 before the treatment and 62.50 ± 43.69 after the treatment and the difference between them was statistically significant (P < .001). After treatment, an
increase in total oxidant status, total antioxidant status, oxidative stress index, interleukin-10, interferon-gamma levels, and a decrease in interleukin-6 and tumor
necrosis factor-α levels were observed, but the difference was not statistically significant (P > .05). While there was no difference in Shannon diversity after the
application of alpha diversity analysis, a decrease was observed in the Chao (P < .006) analysis.
Conclusion: The use of probiotics containing B. subtilis spores in patients with diarrheal-type irritable bowel syndrome reduces the severity of the disease, but
no significant effect was observed in terms of inflammatory parameters.
Keywords: Bacillus subtilis, gut microbiota, irritable bowel syndrome